Chemotherapy-Induced Diarrhea Pipeline Landscape Analysis | DelveInsight
Chemotherapy-Induced Diarrhea pipeline has a limited number of drugs offering pharma players immense opportunities to explore.
Los Angeles, USA, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Chemotherapy-Induced Diarrhea Pipeline Expected to Witness the Entry of Novel Therapies in the Coming Decade | DelveInsight
Chemotherapy-Induced Diarrhea pipeline has a limited number of drugs offering pharma players immense opportunities to explore.
DelveInsight's 'Chemotherapy-induced Diarrhea Pipeline Insights' report offers comprehensive coverage of the emerging Chemotherapy-induced Diarrhea therapeutics space in different stages of development from pre-clinical till a late-end stage, along with dormant, inactive and abandoned drugs agents.
The Chemotherapy-induced Diarrhea Pipeline report provides acomprehensive view of the clinical trials, partnerships and collaborations, recent happenings in the space and growth prospects across the Chemotherapy-induced Diarrhea domain.
Some of the key takeaways from the Chemotherapy-induced Diarrhea Pipeline report:
- The Chemotherapy-induced Diarrhea Pipeline report offers a rich analysis of 5+ key players and 5+ key therapies.
- Chemotherapy-induced Diarrhea pipeline comprises emerging therapies in different stages of the clinical phase such as FW-420, Mytesi, OQL051, DP 1038 and others.
- Some of the key companies working to strengthen the Chemotherapy-induced Diarrhea Pipeline are AzuRx BioPharma, Napo Pharmaceuticals, OnQuality Pharmaceuticals, Dauntless Pharmaceuticals, among others.
Request for Sample report to discover more about the therapies set to grab maximum patient pool @ Chemotherapy-induced Diarrhea Emerging Therapies and Forecast
Chemotherapy-induced Diarrhea (CID) is a side-effect of frequently used chemotherapy agents and can lead to delays in treatment and poor quality of life. It is a common problem, especially in patients with advanced cancer and is most often described with fluoropyrimidines (particularly fluorouracil [FU] and capecitabine) and irinotecan.
For more information on emerging drugs, visit Chemotherapy-induced Diarrhea Pipeline Analysis
Chemotherapy-induced Diarrhea Pipeline Drugs Immunostimulants
| Drug | Company | Phase | MoA | RoA |
| FW-420 | AzuRx BioPharma | Unknown | MTOR protein inhibitors | Oral/rectal |
| Mytesi | Napo Pharmaceuticals | Phase III | Chloride channel antagonists | Oral |
| OQL051 | OnQuality Pharmaceuticals | Discovery | NA | NA |
| DP 1038 | Dauntless Pharmaceuticals | Phase II | Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists | Intranasal |
Request for Sample to know more @ Chemotherapy-induced Diarrhea Pipeline Analysis, Key Companies, and Futuristic Trends
Chemotherapy-induced Diarrhea Therapeutic Assessment
The Chemotherapy-induced Diarrhea Pipeline report lays down complete insights into active Chemotherapy-induced Diarrhea pipeline therapies segmented into Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.
By Product Type
- Mono
- Combination
- Mono/Combination
By Stage
- Discovery
- Pre-clinical
- IND
- Phase I
- Phase II
- Phase III
- Pre-registration
By Molecule Type
- Peptides
- Small molecule
By Route of Administration
- Oral
- Intranasal
- Intravenous
- Subcutaneous
- Intramuscular
By Mechanism of Action
- Chloride channel antagonists
- Growth hormone-releasing hormone inhibitors
- Somatostatin receptor agonists
- MTOR protein inhibitors
By Targets
- Chloride channel
- Growth hormone-releasing hormone
- Somatostatin receptor
- MTOR protein
Scope of the Report
Coverage: Global
Key Players: AzuRx BioPharma, Napo Pharmaceuticals, Dauntless Pharmaceuticals, OnQuality Pharmaceuticals and others.
Key Chemotherapy-induced Diarrhea Pipeline Therapies: FW-420, Mytesi, DP 1038, OQL051 and others.
Reach out @ Chemotherapy-induced Diarrhea Pipeline: Novel therapies and Emerging technologies
Table of Contents
| 1 | Report Introduction |
| 2 | Chemotherapy-induced Diarrhea Disease Overview |
| 3 | Chemotherapy-induced Diarrhea Pipeline Outlook |
| 4 | Comparative Analysis |
| 5 | Chemotherapy-induced Diarrhea Therapeutic Products in Clinical Stage |
| 6 | Chemotherapy-induced Diarrhea Therapeutic Products in Non-clinical Stage |
| 7 | Chemotherapy-induced Diarrhea Therapeutics Pipeline Analysis |
| 8 | Inactive Chemotherapy-induced Diarrhea Pipeline Products |
| 9 | Appendix |
| 10 | Report Methodology |
| 11 | Consulting Services |
| 12 | Disclaimer |
| 13 | About DelveInsight |
Visit to know more of what's covered @ Chemotherapy-induced Diarrhea Emerging Therapies, Treatments and Ongoing Clinical Trials
Related Reports
DelveInsight's Biliary Tract Cancers (BTCs) - Epidemiology Forecast 2030 report.
DelveInsight's Chemotherapy-Induced Hearing Loss Market Insights, Epidemiology and Market Forecast - 2030 report.
DelveInsight's Chronic Heart Failure - Market Insights, Epidemiology and Market Forecast - 2030 report.
DelveInsight's Chronic Phase Chronic Myeloid Leukemia Market Insights, Epidemiology and Market Forecast - 2030 report.
DelveInsight's Iron Overload Syndrome Market Insights, Epidemiology and Market Forecast - 2030 report.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
For more insights, visit Pharma, Healthcare, and Biotech News
Contact Us Shruti Thakur info@delveinsight.com +1(919)321-6187 www.delveinsight.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
